Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP471284.RACk--T0Wys1fDrV8VBZatGKUuFZocs8muFFFJTXfOc4c130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP471284.RACk--T0Wys1fDrV8VBZatGKUuFZocs8muFFFJTXfOc4c130_assertion type Assertion NP471284.RACk--T0Wys1fDrV8VBZatGKUuFZocs8muFFFJTXfOc4c130_head.
- NP471284.RACk--T0Wys1fDrV8VBZatGKUuFZocs8muFFFJTXfOc4c130_assertion description "[Imatinib (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP471284.RACk--T0Wys1fDrV8VBZatGKUuFZocs8muFFFJTXfOc4c130_provenance.
- NP471284.RACk--T0Wys1fDrV8VBZatGKUuFZocs8muFFFJTXfOc4c130_assertion evidence source_evidence_literature NP471284.RACk--T0Wys1fDrV8VBZatGKUuFZocs8muFFFJTXfOc4c130_provenance.
- NP471284.RACk--T0Wys1fDrV8VBZatGKUuFZocs8muFFFJTXfOc4c130_assertion SIO_000772 15946589 NP471284.RACk--T0Wys1fDrV8VBZatGKUuFZocs8muFFFJTXfOc4c130_provenance.
- NP471284.RACk--T0Wys1fDrV8VBZatGKUuFZocs8muFFFJTXfOc4c130_assertion wasDerivedFrom befree-20140225 NP471284.RACk--T0Wys1fDrV8VBZatGKUuFZocs8muFFFJTXfOc4c130_provenance.
- NP471284.RACk--T0Wys1fDrV8VBZatGKUuFZocs8muFFFJTXfOc4c130_assertion wasGeneratedBy ECO_0000203 NP471284.RACk--T0Wys1fDrV8VBZatGKUuFZocs8muFFFJTXfOc4c130_provenance.